Cited by 219Virus-based gene therapy researchParvovirus B19 Infection StudiesRNA Interference and Gene Delivery

The DOI matches its Crossref record; 90 of the 91 references it cites were found in a registry or an index.

Structural Insight into the Unique Properties of Adeno-Associated Virus Serotype 9

Open access

DiMattia, Michael A., Nam, Hyun-Joo, Van Vliet, Kim, Mitchell, Matthew, Bennett, Antonette, Gurda, Brittney L., McKenna, Robert, Olson, Norman H., Sinkovits, Robert S., Potter, Mark, Byrne, Barry J., Aslanidi, George, Zolotukhin, Sergei, Muzyczka, Nicholas, Baker, Timothy S., Agbandje-McKenna, Mavis·2012·Journal of Virology

DOI 10.1128/jvi.07232-11PMC PMC3393551

Open this paper in CoChat — free account Open PDF

Abstract

Adeno-associated virus serotype 9 (AAV9) has enhanced capsid-associated tropism for cardiac muscle and the ability to cross the blood-brain barrier compared to other AAV serotypes. To help identify the structural features facilitating these properties, we have used cryo-electron microscopy (cryo-EM) and three-dimensional image reconstruction (cryo-reconstruction) and X-ray crystallography to determine the structure of the AAV9 capsid at 9.7- and 2.8-Å resolutions, respectively. The AAV9 capsid exhibits the surface topology conserved in all AAVs: depressions at each icosahedral two-fold symmetry axis and surrounding each five-fold axis, three separate protrusions surrounding each three-fold axis, and a channel at each five-fold axis. The AAV9 viral protein (VP) has a conserved core structure, consisting of an eight-stranded, β-barrel motif and the αA helix, which are present in all parvovirus structures. The AAV9 VP differs in nine variable surface regions (VR-I to -IX) compared to AAV4, but at only three (VR-I, VR-II, and VR-IV) compared to AAV2 and AAV8. VR-I differences modify the raised region of the capsid surface between the two-fold and five-fold depressions. The VR-IV difference produces smaller three-fold protrusions in AAV9 that are less “pointed” than AAV2 and AAV8. Significantly, residues in the AAV9 VRs have been identified as important determinants of cellular tropism and transduction and dictate its antigenic diversity from AAV2. Hence, the AAV9 VRs likely confer the unique infection phenotypes of this serotype.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1128/jvi.07232-11

Cites

90 of 90 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

UCSF Chimera—A visualization system for exploratory research and analysis
Pettersen, E. F., Goddard, T. D., Huang, C. C., Couch, G. S., Greenblatt, D. M., Meng, E. C., & Ferrin, T. E. (2004) · Journal of Computational Chemistry · doi:10.1002/jcc.20084 · Cited by 46,047
Coot : model-building tools for molecular graphics
Emsley, P., & Cowtan, K. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904019158 · Cited by 30,571
The CCP4 suite: programs for protein crystallography
Number Collaborative Computational Project (1994) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444994003112 · Cited by 17,317
Crystallography & NMR System: A New Software Suite for Macromolecular Structure Determination
Brünger, A. T., Adams, P. D., Clore, G. M., DeLano, W. L., Gros, P., Grosse‐Kunstleve, R. W., Jiang, J., Kuszewski, J. J., Nilges, M., Pannu, N., et al. (1998) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444998003254 · Cited by 15,723
MolProbity : all-atom structure validation for macromolecular crystallography
Chen, V. B., Arendall, W. B., Headd, J. J., Keedy, D. A., Immormino, R. M., Kapral, G. J., Murray, L. W., Richardson, J. S., & Richardson, D. C. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909042073 · Cited by 14,115
Development of Virus-Like Particle Technology from Small Highly Symmetric to Large Complex Virus-Like Particle Structures
Pushko, P., Pumpens, P., & Grens, E. (2013) · Intervirology · doi:10.1159/000346773 · Cited by 5,975
SWISS-MODEL: an automated protein homology-modeling server
Schwede, T. F. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg520 · Cited by 5,592
Secondary-structure matching (SSM), a new tool for fast protein structure alignment in three dimensions
Krissinel, E., & Henrick, K. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904026460 · Cited by 3,788
Optimal determination of particle orientation, absolute hand, and contrast loss in single-particle electron cryomicroscopy
Rosenthal, P. B., & Henderson, R. (2003) · Journal of Molecular Biology · doi:10.1016/j.jmb.2003.07.013 · Cited by 2,416
The SWISS-MODEL Repository and associated resources
Kiefer, F., Arnold, K., Künzli, M., Bordoli, L., & Schwede, T. F. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn750 · Cited by 2,003

Show all 91 references

Research works printed but not linked: 1

MuzyczkaN BernsK. (ed). 2001. Parvoviridae: the viruses and their replication 4th ed. Lippincott Williams & Wilkins New York NY.

Sorted by citations

Items 101–200 of 218

Improving clinical efficacy of adeno associated vectors by rational capsid bioengineering
Sen, D. (2014) · Journal of Biomedical Science · doi:10.1186/s12929-014-0103-1 · Cited by 28
Physical, chemical, and synthetic virology: Reprogramming viruses as controllable nanodevices
Chen, M. Y., Butler, S. S., Chen, W., & Suh, J. (2018) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1545 · Cited by 28
“Specifically, substantial progress over the last several decades has uncovered that phenotypic divergences in wild type AAV serotypes are correlated with hypervariable loop regions in the capsid (DiMattia et al., 2012; Zinn et al., 2015).”
Background
Functional Analysis of the Putative Integrin Recognition Motif on Adeno-associated Virus 9
Shen, S., Berry, G. E., Rivera, R. M. C., Cheung, R., Troupes, A. N., Brown, S. M., Kafri, T., & Asokan, A. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.608281 · Cited by 26
AAV-8 Is More Efficient than AAV-9 in Transducing Neonatal Dog Heart
Pan, X., Yue, Y., Zhang, K., Hakim, C. H., Kodippili, K., McDonald, T., & Duan, D. (2015) · Human Gene Therapy Methods · doi:10.1089/hgtb.2014.128 · Cited by 27
“26,27 Major differences between two serotypes are located in three surface variable regions.”
AAV-Based Gene Therapy: Opportunities, Risks, and Scale-Up Strategies
Moldavskii, D., Gilazieva, Z., Fattakhova, А. N., Solovyeva, V. V., Issa, S. S., Sufianov, A. A., Суфианова, Г. З., & Rizvanov, A. A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178282 · Cited by 28
AAV Vector-Mediated Antibody Delivery (A-MAD) in the Central Nervous System
Marino, M., & Holt, M. G. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.870799 · Cited by 24
Ancestral Library Identifies Conserved Reprogrammable Liver Motif on AAV Capsid
Zinn, E. M., Unzu, C., Schmit, P. F., Turunen, H., Zabaleta, N., Sanmiguel, J. C., Fieldsend, A., Bhatt, U., Diop, C. T., Merkel, E., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100803 · Cited by 28
Downstream processing of AAV based gene therapy vectors
Jungbauer, A., & Wheelwright, S. M. (2025) · Separation and Purification Technology · doi:10.1016/j.seppur.2025.133051 · Cited by 24
Targeting the lung epithelium after intravenous delivery by directed evolution of underexplored sites on the AAV capsid
Goertsen, D., Goeden, N., Flytzanis, N. C., & Gradinaru, V. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.07.010 · Cited by 24
Site Specific Modification of Adeno-Associated Virus Enables Both Fluorescent Imaging of Viral Particles and Characterization of the Capsid Interactome
Chandran, J. S., Sharp, P. S., Karyka, E., Alves-Cruzeiro, J., Coldicott, I., Castelli, L. M., Hautbergue, G. M., Collins, M. O., & Azzouz, M. (2017) · Scientific Reports · doi:10.1038/s41598-017-15255-2 · Cited by 21
rAAV-Mediated Cochlear Gene Therapy: Prospects and Challenges for Clinical Application
Blanc, F., Mondain, M., Bemelmans, A., Affortit, C., Puel, J., & Wang, J. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9020589 · Cited by 21
“The sugar-binding preferences of different variants of AAV are dependent on their capsid sequence, which may impact the cell-type transduction preferences of different serotypes of AAV [26,27].”
Background
Of rAAV and Men: From Genetic Neuromuscular Disorder Efficacy and Toxicity Preclinical Studies to Clinical Trials and Back
Buscara, L., Gross, D., & Danièle, N. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10040258 · Cited by 22
Evaluation of an AAV9-mini-dystrophin gene therapy candidate in a rat model of Duchenne muscular dystrophy
Guiner, C. L., Xiao, X., Larcher, T., Lafoux, A., Huchet, C., Toumaniantz, G., Adjali, O., Anegón, I., Remy, S., Grieger, J., et al. (2023) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2023.05.017 · Cited by 21
“24,25 36 The dystrophic phenotype in this model can be detected as soon as 10 days of age, with obvious pathologic features noted at 1.5 months that progress with advancing age.”
BackgroundInfluential
AAV8 capsid variable regions at the two-fold symmetry axis contribute to high liver transduction by mediating nuclear entry and capsid uncoating
Tenney, R. M., Bell, C. L., & Wilson, J. M. (2014) · Virology · doi:10.1016/j.virol.2014.02.017 · Cited by 22
Cardiac bridging integrator 1 gene therapy rescues chronic non-ischemic heart failure in minipigs
Li, J., Balmaceda, P., Ha, T., Visker, J. R., Maalouf, N., Kwan, E., Hoareau, G. L., Accad, M. F., Ranjan, R., Selzman, C. H., et al. (2024) · npj Regenerative Medicine · doi:10.1038/s41536-024-00380-0 · Cited by 20
Characterization of the Serpentine Adeno-Associated Virus (SAAV) Capsid Structure: Receptor Interactions and Antigenicity
Mietzsch, M., Hull, J. A., Makal, V., Ybargollin, A. J., Yu, J. C., McKissock, K., Bennett, A. D., Pénzes, J. J., Lins, B., Yu, Q., et al. (2022) · Journal of Virology · doi:10.1128/jvi.00335-22 · Cited by 19
Self-citation
Infusion reactions to adeno‐associated virus (AAV)‐based gene therapy: Mechanisms, diagnostics, treatment and review of the literature
Notarte, K. I., Catahay, J. A., Macasaet, R., Liu, J., Velasco, J. V., Peligro, P. J., Vallo, J., Goldrich, N., Lahoti, L., Zhou, J., et al. (2023) · Journal of Medical Virology · doi:10.1002/jmv.29305 · Cited by 19
“53,77 5 | THERAPEUTIC CONSIDERATIONS 26 resolve within a few days and do not recur.”
Background
Crystal Structure of Major Envelope Protein VP24 from White Spot Syndrome Virus
Sun, L., Su, Y., Zhao, Y., Fu, Z., & Wu, Y. (2016) · Scientific Reports · doi:10.1038/srep32309 · Cited by 19
A CRISPR Screen Identifies the Cell Polarity Determinant Crumbs 3 as an Adeno-associated Virus Restriction Factor in Hepatocytes
Madigan, V. J., Tyson, T. O., Yuziuk, J. A., Pillai, M., Møller-Tank, S., & Asokan, A. (2019) · Journal of Virology · doi:10.1128/jvi.00943-19 · Cited by 19
Systemic γ-sarcoglycan AAV gene transfer results in dose-dependent correction of muscle deficits in the LGMD 2C/R5 mouse model
Seo, Y.-E., Baine, S. H., Kempton, A. N., Rogers, O. C., Lewis, S., Adegboye, K., Haile, A., Griffin, D. A., Peterson, E. L., Pozsgai, E. R., et al. (2023) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2023.01.004 · Cited by 18
Identifying Viral Vector Characteristics by Nanopore Sensing
Tsutsui, M., Wada, M., Arima, A., Tsunekawa, Y., Sasaki, T., Sakamoto, K., Yokota, K., Baba, Y., Kawai, T., & Okada, T. (2024) · ACS Nano · doi:10.1021/acsnano.4c01888 · Cited by 18
Characterization of Naturally-Occurring Humoral Immunity to AAV in Sheep
Tellez, J., Van Vliet, K., Tseng, Y.-S., Finn, J. D., Tschernia, N., Almeida-Porada, G., Arruda, V. R., Agbandje-McKenna, M., & Porada, C. D. (2013) · PLoS ONE · doi:10.1371/journal.pone.0075142 · Cited by 18
Self-citation
Insight Into the Degradation Pathways of an AAV9
Rodriguez, A., Jalimarada, S. S., Banazadeh, A., Afroz, S., Ali, A., Deng, K., Huang, L., Galibert, L., Singh, R., & Zhou, C. (2024) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2024.05.034 · Cited by 16
Structural characterization of a bat Adeno-associated virus capsid
Mietzsch, M., Li, Y., Kurian, J. J., Smith, J. K., Chipman, P. R., McKENNA, R. V., Yang, L., & Agbandje‐McKenna, M. (2020) · Journal of Structural Biology · doi:10.1016/j.jsb.2020.107547 · Cited by 17
Self-citation
Electron microscopy analysis of a disaccharide analog complex reveals receptor interactions of adeno-associated virus
Xie, Q., Spilman, M. S., Meyer, N., Lerch, T. F., Stagg, S. M., & Chapman, M. S. (2013) · Journal of Structural Biology · doi:10.1016/j.jsb.2013.09.004 · Cited by 17
AAV vectors engineered to target insulin receptor greatly enhance intramuscular gene delivery
Jackson, C. B., Richard, A. S., Ojha, A., Conkright, K. A., Trimarchi, J. M., Bailey, C. C., Alpert, M. D., Kay, M. A., Farzan, M., & Choe, H. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.11.004 · Cited by 16
Biophysical characterization of adeno-associated virus capsid through the viral transduction life cycle
Xiang, Y. S., & Hao, G. G. (2023) · Journal of Genetic Engineering and Biotechnology · doi:10.1186/s43141-023-00518-5 · Cited by 18
Context-Specific Function of the Engineered Peptide Domain of PHP.B
Martino, R. A., Fluck, E. C., Murphy, J., Wang, Q., Hoff, H. B., Pumroy, R. A., Lee, C. Y., Sims, J. J., Roy, S., Moiseenkova‐Bell, V. Y., et al. (2021) · Journal of Virology · doi:10.1128/jvi.01164-21 · Cited by 17
Therapeutic Application and Structural Features of Adeno-Associated Virus Vector
Matsuzaka, Y., & Yashiro, R. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46080499 · Cited by 15
Optical Quantification by Nanopores of Viruses, Extracellular Vesicles, and Nanoparticles
Chazot-Franguiadakis, L., Eid, J., Socol, M., Molcrette, B., Guégan, P., Mougel, M., Salvetti, A., & Montel, F. (2022) · Nano Letters · doi:10.1021/acs.nanolett.2c00253 · Cited by 14
Multimodal imaging of capsid and cargo reveals differential brain targeting and liver detargeting of systemically-administered AAVs
Seo, J. W., Ajenjo, J., Wu, B., Robinson, E. R., Raie, M. N., Wang, J., Tumbale, S. K., Buccino, P. J., Anders, D., Shen, B., et al. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121701 · Cited by 15
Adeno-associated virus receptor complexes and implications for adeno-associated virus immune neutralization
Large, E. E., & Chapman, M. S. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1116896 · Cited by 16
Direct deamidation analysis of intact adeno-associated virus serotype 9 capsid proteins using reversed-phase liquid chromatography
Zhou, Y., & Wang, Y. (2023) · Analytical Biochemistry · doi:10.1016/j.ab.2023.115099 · Cited by 15
Adeno-associated virus serotype 9 antibody seroprevalence for patients in the United States with spinal muscular atrophy
Day, J., Mendell, J. R., Burghes, A. H. M., van Olden, R. W., Adhikary, R. R., & Dilly, K. W. (2023) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2023.101117 · Cited by 14
Molecular Signature of Astrocytes for Gene Delivery by the Synthetic Adeno‐Associated Viral Vector rAAV9P1
Bauer, A., Puglisi, M., Nagl, D., Schick, J., Werner, T. A., Klingl, A., Andari, J. E., Hornung, V., Kessler, H., Götz, M., et al. (2022) · Advanced Science · doi:10.1002/advs.202104979 · Cited by 14
AAV6 Is Superior to Clade F AAVs in Stimulating Homologous Recombination-Based Genome Editing in Human HSPCs
Dudek, A. M., & Porteus, M. H. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.09.005 · Cited by 14
Tissue and cell-type-specific transduction using rAAV vectors in lung diseases
Kochergin-Nikitsky, K. S., Belova, L., Лавров, А. В., & Smirnikhina, S. (2021) · Journal of Molecular Medicine · doi:10.1007/s00109-021-02086-y · Cited by 14
Cardiac Gene Therapy With Relaxin Receptor 1 Overexpression Protects Against Acute Myocardial Infarction
Devarakonda, T., Mauro, A. G., Cain, C. K., Das, A., & Salloum, F. N. (2021) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2021.10.012 · Cited by 13
Adeno-Associated Virus-Mediated Gene Therapy
Zaman, H., Khan, A. U., Khan, K., Toheed, S., Abdullah, M., Zeeshan, H. M., Hameed, A., Umar, M., Shahid, M., Malik, K. A., et al. (2023) · Critical Reviews in Eukaryotic Gene Expression · doi:10.1615/critreveukaryotgeneexpr.2023048135 · Cited by 12
Sample Preparation Matters for Peptide Mapping to Evaluate Deamidation of Adeno-Associated Virus Capsid Proteins Using Liquid Chromatography–Tandem Mass Spectrometry
Zhou, Y., & Wang, Y. (2022) · Human Gene Therapy · doi:10.1089/hum.2021.207 · Cited by 12
A link between severe hepatitis in children and adenovirus 41 and adeno-associated virus 2 infections
Grand, R. J. A. (2022) · Journal of General Virology · doi:10.1099/jgv.0.001783 · Cited by 11
Characterizing Glycosylation of Adeno-Associated Virus Serotype 9 Capsid Proteins Generated from HEK293 Cells through Glycopeptide Mapping and Released Glycan Analysis
Zhou, Y., Priya, S., & Ong, J. Y. (2024) · Microorganisms · doi:10.3390/microorganisms12050946 · Cited by 12
“Furthermore, there are more than 13 AAV serotypes that show 51–99% capsid amino acid sequence identity [3,5,9].”
Background
Removal of empty capsids from high‐dose adeno‐associated virus 9 gene therapies
Kish, W. S., Lightholder, J., Zeković, T., Berrill, A., Roach, M. K., Wellborn, W. B., & Vorst, E. (2024) · Biotechnology and Bioengineering · doi:10.1002/bit.28737 · Cited by 12
“The unintuitive rAAV9 elution order reported here and by Lock and Alvira might be driven by capsid structure (DiMattia et al., 2012).”
Evading the AAV Immune Response in Mucopolysaccharidoses
Piechnik, M., Sawamoto, K., Ohnishi, H., Kawamoto, N., Ago, Y., & Tomatsu, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103433 · Cited by 12
“AAV8 has been shown to transduce liver cells 10- to 100-fold more efficiently than other serotypes [34,35], whereas AAV9 has demonstrated active crossing of the blood–brain barrier, targeting the central nervous system [36,37].”
Background
Emerging Concepts in Vector Development for Glial Gene Therapy: Implications for Leukodystrophies
von Jonquières, G., Rae, C. D., & Housley, G. D. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.661857 · Cited by 12
Structural Changes Likely Cause Chemical Differences between Empty and Full AAV Capsids
Heldt, C. L., Skinner, M. A., & Anand, G. S. (2024) · Biomedicines · doi:10.3390/biomedicines12092128 · Cited by 12
Gene therapy for kidney disease: targeting cystinuria
Peek, J. L., & Wilson, M. H. (2021) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000768 · Cited by 17
Expression and Purification of Adeno-associated Virus Virus-like Particles in a Baculovirus System and AAVR Ectodomain Constructs in E. coli
Meyer, N., Davulcu, O., Xie, Q., Silveria, M., Zane, G. M., Large, E. E., & Chapman, M. S. (2020) · BIO-PROTOCOL · doi:10.21769/bioprotoc.3513 · Cited by 9
Cryo-EM structure of adeno-associated virus 4 at 2.2 Å resolution
Zane, G. M., Silveria, M., Meyer, N., White, T., Duan, R., Zou, X., & Chapman, M. S. (2023) · Acta Crystallographica Section D Structural Biology · doi:10.1107/s2059798322012190 · Cited by 9
Acoustically Targeted Chemogenetics for Noninvasive Control of Neural CircuitsPreprint
Szablowski, J. O., Lue, B., Lee‐Gosselin, A., Malounda, D., & Shapiro, M. G. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/241406 · Cited by 9
Soft jamming of viral particles in nanopores
Chazot-Franguiadakis, L., Eid, J., Delecourt, G., Kolbeck, P. J., Brugère, S., Molcrette, B., Socol, M., Mougel, M., Salvetti, A., Démery, V., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-50059-9 · Cited by 8
Advances in designing Adeno-associated viral vectors for development of anti-HBV gene therapeutics
Mnyandu, N., Limani, S. W., Arbuthnot, P. B., & Maepa, M. B. (2021) · Virology Journal · doi:10.1186/s12985-021-01715-9 · Cited by 9
SMRT Sequencing Enables High-Throughput Identification of Novel AAVs from Capsid Shuffling and Directed Evolution
Casy, W., Garza, I. T., Chen, X., Dong, T., Hu, Y., Kanchwala, M., Trygg, C. B., Shyng, C., Xing, C., Bunnell, B. A., et al. (2023) · Genes · doi:10.3390/genes14081660 · Cited by 8
The amazing AAV capsids: Into the structure-verse
Hsi, J., Mietzsch, M., & McKENNA, R. V. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101629 · Cited by 9
“46 69 However, the structural portfolio was complemented by AAVrh.39, which differs from AAV10 by only a single aa substitution (A589T) in the VP3 region.”
Self-citation
Adeno-associated virus vectors for human gene therapy
Chen, H. (2015) · World Journal of Medical Genetics · doi:10.5496/wjmg.v5.i3.28 · Cited by 8
Bioengineering strategies for gene delivery
Shams, S., & Silva, E. A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816221-7.00004-5 · Cited by 8
Multifunctional nanoparticle platform for targeted delivery and vaccines
Redecker, A. S., Neek, M., Smith, P. E. J., & Swartz, J. R. (2025) · iScience · doi:10.1016/j.isci.2025.112599 · Cited by 6
Directed evolution of novel AAV variants using the MCMS library for enhanced CNS tropism and reduced liver targeting in mice
Song, Q., Wu, J., Zhang, Q., Wu, S. V., Luo, X., Xu, M., Xu, Y., Wang, G., Yu, H., Chen, H., et al. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101522 · Cited by 7
“52 The prediction was based on the AAV9 VP1 reference model (PDB accession number 3UX1), 25 and all structures were aligned and visualized using PyMOL software.”
An AAV capsid proposed as microglia-targeting directs genetic expression in forebrain excitatory neurons
Cao, W., Tan, Z., Berackey, B. T., Nguyen, J. K., Brown, S. R., Du, S., Lin, B., Ye, Q., Seiler, M. J., Holmes, T. C., et al. (2025) · Cell Reports Methods · doi:10.1016/j.crmeth.2025.101054 · Cited by 5
“This insertion site has been reported to mediate AAV vector recognition by receptors on the cell membrane and post-attachment processing along the 3-fold symmetry axis 36,37 based on the position of pro-trusions of the capsid’s 3-fold symmetry axis.”
Structural basis of liver de-targeting and neuronal tropism of CNS-targeted AAV capsids
Brittain, T. J., Jang, S., Coughlin, G. M., Hoang, J. D., Barcelona, B. H., Giriat, I., Ristic, F., Appling, N., Chossis, C. P., Shay, T. F., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.03.030 · Cited by 7
“1, is closely apposed to AAVR-PKD2, we next compared the binding affinity of CAP-B10 for AAVR-PKD2 with that of its ancestral capsids, AAV9 and PHP.eB, measuring equilibrium dissociation constants (K d ) by biolayer interferometry (BLI) (Figure 2A, Table S2).”
Discovering human cell‐compatible gene therapy virus variants via optimized screening in mouse models
Dai, M., Yang, N., Xu, K., Zhang, J., Li, X., Zhang, Y., & Li, W. (2023) · Cell Proliferation · doi:10.1111/cpr.13565 · Cited by 4
“33,36 Modifications of the VR-VIII, which is located at the top of the 3-fold axis of the AAV capsid protein, can change the infection ability of AAV on cells.”
Background
Viral Vector Technologies and Strategies: Improving on Nature
Croze, R. H., Kotterman, M. A., Burns, C. H., Schmitt, C. E., Quezada, M., Schaffer, D. V., Kirn, D. H., & Francis, P. J. (2021) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000361 · Cited by 5
Manufacturing Considerations and Challenges for AAV Ocular Gene Therapy
Rodrigues, G. A., Shalaev, E., Karami, T. K., Cunningham, J., Rivers, H. M., Feng, S., Shah, D., & Slater, N. K. H. (2021) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-3-030-76367-1_22 · Cited by 5
Gene therapy and respiratory neuroplasticity
Mantilla, C. B. (2016) · Experimental Neurology · doi:10.1016/j.expneurol.2016.09.014 · Cited by 5
I Am Here: It Took a Global Village
Agbandje‐McKenna, M. (2021) · Annual Review of Virology · doi:10.1146/annurev-virology-091919-104940 · Cited by 5
Self-citation
Recent Advances in Canine Medicine
Fonseca‐Alves, C. E. (2022) · Veterinary medicine and science · doi:10.5772/intechopen.100825 · Cited by 6
Reprogramming Adeno-Associated Virus Tropism Via Displayed Peptides Tiling Receptor-LigandsPreprint
Portell, A. J., Ford, K. M., Suhardjo, A., Rainaldi, J., Bublik, M. N., Sanghvi, M., Kumar, A., Wing, M. K., Palmer, N. D., Le, D. A., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.09.26.509383 · Cited by 5
Cardiac-targeted delivery of advanced medical therapies for heart disease
Liu, X., Yan, M., Lu, S., & Hausenloy, D. J. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag432 · Cited by 5
Effects of intracardiac delivery of aldehyde dehydrogenase 2 gene in myocardial salvage
Pan, G., Roy, B., Harding, P., Lanigan, T. M., Hilgarth, R., Thandavarayan, R. A., & Palaniyandi, S. S. (2022) · Gene Therapy · doi:10.1038/s41434-022-00345-2 · Cited by 4
Adeno-associated virus vector-based gene therapy for hereditary diseases: current problems of application and approaches to solve them
Egorova, T. V., Piskunov, A. A., & Poteryaev, D. A. (2024) · Biological Products Prevention Diagnosis Treatment · doi:10.30895/2221-996x-2024-24-2-123-139 · Cited by 5
Retinal Penetrating Adeno-Associated Virus
Kumar, B., Mishra, M., Cashman, S. M., & Kumar‐Singh, R. (2024) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.65.10.30 · Cited by 4
“20 The results indicated a large but potentially viable insertion (in blue in Fig.”
BackgroundMethod
Hitching a Ride: Enhancing Nucleic Acid Delivery into Target Cells Through Nanoparticles
Penumarthi, A., Basak, P., Smooker, P. M., & Shukla, R. (2020) · Environmental chemistry for a sustainable world · doi:10.1007/978-3-030-29207-2_11 · Cited by 4
Adeno-associated virus serotype 9 structural heterogeneity and stability characterized by charge detection mass spectrometry
Miller, Z. M., Lin, L. F., Schaffer, D. V., & Williams, E. R. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101608 · Cited by 6
The delivery challenge of adeno-associated virus vector-based gene therapies for neurological diseases
Pak, A., Wear, D., Tahmasian, N., Min, J. Y., Premraj, D. K., Gibbs, R., Spencer, K. A., Fang, S., Zerbes, T., Krishnan, M. R., et al. (2026) · Frontiers in Neuroscience · doi:10.3389/fnins.2026.1768545 · Cited by 3
“In particular, hypervariable regions (VR) IV and VIII have been shown to mediate docking (Figure 1) (DiMattia et al., 2012).”
Adeno-associated virus serotype 2 capsids with proteolytic cuts by trypsin remain intact and potent
Zhou, Y., Sach, T., Ong, J. Y., Lim, T.-A., Berecz, Z., Deniston, C., Miličić, G., Tsai, C. Y., Kandepalli, T., Langeslay, D. J., et al. (2024) · Gene Therapy · doi:10.1038/s41434-024-00507-4 · Cited by 4
“The AAV icosahedral capsid is formed by three viral proteins, VP1, VP2, and VP3 at an approximate 1:1:10 ratio [5].”
Application of aqueous two-phase extraction for separation and purification of various adeno-associated viruses
Fu, X., Leong, H.-Y., Qiao, L., Zhou, J.-N., Hu, W., Yao, S., & Lin, D. (2025) · Biotechnology Letters · doi:10.1007/s10529-024-03555-3 · Cited by 3
“…in the protrusions on the capsid surface among different AAV serotypes could result in varying degrees of steric hindrance (Walters et al. 2004; DiMattia et al. 2012); (3) variations or absence of amino acid residue on the capsid surface of AAV5, AAV8 and AAV9 may lead to differences in…”
El papel de la RSE en América Latina: ¿diferente al de Europa?
Vives, A. (2008) · Dialnet (Universidad de la Rioja) · Cited by 3
Crossing the Blood-Brain Barrier with AAVs: What’s After SMA?
Chan, Y. A., & Deverman, B. E. (2022) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-3-030-88773-5_21 · Cited by 3
Design and Production of Heart Chamber-Specific AAV9 Vectors
Bilal, A. S., Thuerauf, D. J., Blackwood, E. A., & Glembotski, C. C. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2707-5_8 · Cited by 3
An integrin-targeting AAV developed using a novel computational rational design methodology presents improved targeting of the skeletal muscle and reduced liver tropismPreprint
Hong, A. V., Suel, L., Poupiot, J., & Richard, I. (2023) · Research Square · doi:10.21203/rs.3.rs-3466229/v1 · Cited by 3
Gene Therapy for Heart Failure: Impact on Mitochondrial Dysfunction
Blagonravov, M. L., Sklifasovskaya, A. P., Karpov, R. M., Ovechkina, V. S., Andrianova, S. K., Syatkin, S. P., Belousov, V. V., & Mozhaev, A. A. (2026) · Biomedicines · doi:10.3390/biomedicines14020344 · Cited by 2
“Discovered in 2004, the AAV9 serotype has emerged as a leading vector for systemic gene delivery, distinguished primarily by its exceptional tissue tropism [91,96,97].”
Effects of chemogenetic inhibition of serotonergic raphe-striatal neurons on L-DOPA-induced behaviors and neurochemistry in a rat model of Parkinson’s disease
Budrow, C., Bernal-Conde, L. D., Sandoval, I. M., Galfano, A., Grezenko, H., Velazquez, A., Marmion, D. J., Flores-Barrera, E., Venkatesh, S., Coyle, M., et al. (2026) · Acta Neuropathologica Communications · doi:10.1186/s40478-026-02221-1 · Cited by 2
Imaged Capillary Isoelectric Focusing (icIEF) Platform for Characterization of Charge Variants of Adeno-Associated Virus (AAV) Capsids and Impact on their Transduction Efficiency
Hoyle, B., Bello, D., Hill, J., Das, S., & Kim, J. (2025) · Current Gene Therapy · doi:10.2174/0115665232369708250327081305 · Cited by 2
Enhanced Separation of AAV Capsids Using Analytical Anion Exchange Monolithic Columns: Emphasis on Organic Modifiers
Žvanut, T., Peljhan, S., Lebar, S., Štrancar, A., & Livk, A. G. (2025) · Analytica Chimica Acta · doi:10.1016/j.aca.2025.344585 · Cited by 2
Hearing impairment: new frontiers of regenerative medicine
Franzè, A., Miceli, M., VECCHIO, V. D., Auletta, G., Laria, C., Malesci, R., & Marciano, E. (2021) · Otorhinolaryngology · doi:10.23736/s2724-6302.21.02381-1 · Cited by 1
Role of viral protein ratio in the structure and separation of empty and full adeno-associated virus capsids: A molecular dynamics study
Parambathu, A. V., Kumar, V., Khanal, O., & Lenhoff, A. M. (2025) · Molecular Therapy Advances · doi:10.1016/j.omta.2025.201656 · Cited by 2
PEP-TP56 enhances AAV transduction in a serotype-independent manner
Olarewaju, O., Held, F., Schoen, C., Maier, U., & du Plessis, F. (2026) · Heliyon · doi:10.1016/j.heliyon.2025.e44471 · Cited by 1
Metagenomic Reconstruction of Adeno-Associated Virus Genomes
Maiakovska, O., Link, L., Zayas, M., Sano, Y., Koay, T. W., Rapti, K., Liu, J., Bubeck, F., Xu, M., Baumgartl, C., et al. (2026) · Human Gene Therapy · doi:10.1177/10430342261419534 · Cited by 1
“45,46 To standardize the procedure for further structural analysis, both predicted and known structures were truncated at the N-terminus to start with H229, a residue preceding the onset of the ﬁ rst secondary structural element.”
In vivo adenine base editing of mutant Galc gene ameliorates Krabbe disease progression
Nam, B.-G., Seo, J., Hong, S.-A., Kim, J., Kang, M., Notario, G. R., Hong, Y., Cho, S., Bae, S., & Cho, S.-R. (2026) · Genome Medicine · doi:10.1186/s13073-026-01620-2 · Cited by 1
“In order to deliver split ABE genes to the diseased mouse model, we selected the CNS-targeting AAV9 vector due to its wide application at both preclinical and clinical stages of treatment for various diseases [68].”
Viral Vectors for Muscle Gene Therapy
Wang, D., Brown, A., & Gao, G. (2019) · Springer eBooks · doi:10.1007/978-3-030-03095-7_10 · Cited by 1
Elastin‐Like Polypeptides Facilitate Adeno‐Associated Virus Transduction in the Presence of Pre‐Existing Neutralizing Antibodies
Wang, K., Zheng, M., Askew, C., Zhang, X., Li, C., & Han, Z. (2022) · Advanced Therapeutics · doi:10.1002/adtp.202200128 · Cited by 1
Structural studies of Parvoviridae capsid assembly and evolution: implications for novel AAV vector design
Noriega, H. A., Qizhao, W., Yu, D., & Wang, X. S. (2025) · Frontiers in Artificial Intelligence · doi:10.3389/frai.2025.1559461 · Cited by 2
Combination of hydrophilic interaction liquid chromatography and top-down mass spectrometry for characterisation of adeno-associated virus capsid proteins
Beaumal, C., Guapo, F., Smith, J., Carillo, S., & Bones, J. (2025) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-025-05874-4 · Cited by 1
“This finding aligns with the expected theoretical ratio between capsid proteins for functioning AAV9 as documented in the literature [43].”
Structural and Functional Characterization of Porcine Adeno-Associated Viruses
Nelson, A. R., Mietzsch, M., Hsi, J., Eby, J., Chipman, P. R., & McKENNA, R. V. (2025) · Viruses · doi:10.3390/v17091260 · Cited by 1
“When structurally aligned with previously determined capsid structures, such as those of AAV5 and AAV9 [46,47], the capsid cores are nearly perfectly superposable (Figure 2A).”
Self-citation
Adeno-associated viruses escort nanomaterials to specific cells and tissuesPreprint
Nagao, K., Paniagua, E. V., Lei, K., Beckham, J. L., Worthington, P., Manthey, M., Ye, M., Koehler, F., Kim, Y. J., Malkin, E., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.04.04.647267 · Cited by 2
Prevention and inhibition of adverse humoral immune response to gene therapy mediated by adeno-associated virus (AAV) vector
Meliani, A. (2026) · doi:10.70675/83ee599czfe90z44e6za201z0938409e1748
Development of Therapies for Spinal Muscular Atrophy Using Gene Therapy and Nanotechnology
Little, D. (2013) · White Rose eTheses Online (University of Leeds, The University of Sheffield, University of York)
UNCOVERING STRUCTURAL COMPONENTS OF THE ADENO-ASSOCIATED VIRAL CAPSID THAT CAN BE MODIFIED TO IMPROVE CLINICAL GENE THERAPY OUTCOMES
Warischalk, J. K. (2015) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/dqdt-1s58
DETERMINANTS OF AAV TRANSPORT ACROSS THE BLOOD-BRAIN BARRIER
Albright, B. H. (2018) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/vnpr-wx33
The mechanistic role of MicroRNAs in takotsubo syndrome
Couch, L. S. (2018) · Spiral (Imperial College London) · doi:10.25560/73216

Authors: DiMattia, M. A., Nam, H.-J., Van Vliet, K., Mitchell, M., Bennett, A., Gurda, B. L., McKenna, R., Olson, N. H., Sinkovits, R. S., Potter, M., Byrne, B. J., Aslanidi, G., Zolotukhin, S., Muzyczka, N., Baker, T. S., & Agbandje-McKenna, M.
Affiliations: University of Florida (US)
Department of Biochemistry and Molecular Biology, Center for Structural Biology, McKnight Brain Institute, College of Medicine, University of Florida, Gainesville, Florida, USA
University of California San Diego (US)
University of Florida Health (US)
ORCID: DiMattia, Michael A.
Bennett, Antonette
Gurda, Brittney L.
McKenna, Robert
Sinkovits, Robert S.
Potter, Mark
Byrne, Barry J.
Aslanidi, George
Baker, Timothy S.
Venue: Journal of Virology
Publisher: American Society for Microbiology
Published: 2012-06-15
Volume: 86
Issue: 12
Pages: 6947-6958
ISSN: 0022-538X (ISSN-L)
1098-5514
DOI: 10.1128/jvi.07232-11
PMC: PMC3393551
OpenAlex: W2012799865
Cited by: 219
References: 91
Citations by year: 2026: 15 · 2025: 18 · 2024: 17 · 2023: 16 · 2022: 26 · 2021: 23 · 2020: 18 · 2019: 16 · 2018: 15 · 2017: 6 · 2016: 11 · 2015: 9 · 2014: 12 · 2013: 11 · 2012: 4
FWCI: 6.94
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: journals.asm.org/non-commercial-tdm-license (tdm)
Locations: Journal of Virology (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
eScholarship (California Digital Library) (submittedVersion)
Funders: National Science Foundation
National Institutes of Health (4r37gm033050-27)
University of California, San Francisco
National Heart, Lung, and Blood Institute (P01HL059412, P01 HL 59412)
National Institute of General Medical Sciences (R37GM-033050, R37 GM-33050, DMR-0225180, R01GM082946)
Division of Materials Research
National Center for Research Resources (RR-01646, S10RR020016, P41RR001646, P41RR001081)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
Health Sciences › Medicine › Infectious Diseases › Parvovirus B19 Infection Studies
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Keywords: AAV9, viral tropism, blood-brain barrier penetration, antigenic diversity, 3D reconstruction
MeSH terms: Dependovirus, Capsid, Crystallography, X-Ray, Cryoelectron Microscopy, Imaging, Three-Dimensional, Capsid Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Structural Insight into the Unique Properties of Adeno-Associated Virus Serotype 9

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks